APA (7th ed.) Citation

JM, N., J, S., AJ, C., J, F., M, A., U, B., . . . OA, C. (2023). Immunogenicity and reactogenicity of a first booster with BNT162b2 or full-dose mRNA-1273: A randomised VACCELERATE trial in adults ≥75 years (EU-COVAT-1). Vaccine, 41(48), 7166. https://doi.org/10.1016/j.vaccine.2023.10.029

Chicago Style (17th ed.) Citation

JM, Neuhann, et al. "Immunogenicity and Reactogenicity of a First Booster with BNT162b2 or Full-dose MRNA-1273: A Randomised VACCELERATE Trial in Adults ≥75 years (EU-COVAT-1)." Vaccine 41, no. 48 (2023): 7166. https://doi.org/10.1016/j.vaccine.2023.10.029.

MLA (9th ed.) Citation

JM, Neuhann, et al. "Immunogenicity and Reactogenicity of a First Booster with BNT162b2 or Full-dose MRNA-1273: A Randomised VACCELERATE Trial in Adults ≥75 years (EU-COVAT-1)." Vaccine, vol. 41, no. 48, 2023, p. 7166, https://doi.org/10.1016/j.vaccine.2023.10.029.